Research ExplorerPublicationsEffect of external beam radiotherapy on second primary cance...

Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy

Standard

Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. / Preisser, Felix; Mazzone, Elio; Knipper, Sophie; Nazzani, Sebastiano; Bandini, Marco; Shariat, Shahrokh F; Marchioni, Michele; Tian, Zhe; Saad, Fred; Taussky, Daniel; Briganti, Alberto; Huland, Hartwig; Graefen, Markus; Tilki, Derya; Karakiewicz, Pierre I.

In: CUAJ-CAN UROL ASSOC, Vol. 14, No. 5, 05.2020, p. E173-E179.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Preisser, F, Mazzone, E, Knipper, S, Nazzani, S, Bandini, M, Shariat, SF, Marchioni, M, Tian, Z, Saad, F, Taussky, D, Briganti, A, Huland, H, Graefen, M, Tilki, D & Karakiewicz, PI 2020, 'Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy', CUAJ-CAN UROL ASSOC, vol. 14, no. 5, pp. E173-E179. https://doi.org/10.5489/cuaj.6087

APA

Preisser, F., Mazzone, E., Knipper, S., Nazzani, S., Bandini, M., Shariat, S. F., Marchioni, M., Tian, Z., Saad, F., Taussky, D., Briganti, A., Huland, H., Graefen, M., Tilki, D., & Karakiewicz, P. I. (2020). Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. CUAJ-CAN UROL ASSOC, 14(5), E173-E179. https://doi.org/10.5489/cuaj.6087

Vancouver

Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, Shariat SF et al. Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. CUAJ-CAN UROL ASSOC. 2020 May;14(5):E173-E179. https://doi.org/10.5489/cuaj.6087

Bibtex

@article{44f65de2230a4e8aa95dfbb5d303773e,
title = "Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy",
abstract = "INTRODUCTION: We aimed to investigate the effect of radiotherapy (RT) in contemporary patients treated with radical prostatectomy (RP) compared to RP alone for non-metastatic prostate cancer (PCa) on the incidence of second primary cancers (SPCs).METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015), we identified patients with PCa as the only or first primary cancer, who underwent RP and RT or RP alone. Cumulative incidence plots and multivariable Cox regression models tested for SPC rate differences according to treatment type: RP and RT vs. RP alone. Subgroup analyses focused on pelvic, primary pelvic, and non-pelvic SPCs, as well as on late SPCs (>5 years after PCa diagnosis).RESULTS: Of 152 161 patients, 7.1% (n=10 870) received RP and RT. Overall, 6.6 vs. 5.0% developed SPCs after RP and RT vs. RP alone, respectively (p<0.001). Cumulative incidence rates at 10 years after PCa diagnosis for RP and RT vs. RP were 12.0 vs. 8.7% (p<0.001), 2.0 vs. 1.2% (p<0.001), 2.1 vs. 1.3% (p<0.001), and 9.9 vs. 7.4% (p<0.001) for overall SPCs, primary pelvic SPCs, overall pelvic SPCs, and non-pelvic SPCs, respectively. Multivariable Cox regression models revealed an increased risk after RP and RT vs. RP alone for overall (hazard ratio [HR] 1.2; p<0.001), primary pelvic (HR 1.5; p<0.01), pelvic (HR1.4; p<0.001), non-pelvic (HR1.1; p<0.01), late overall (HR 1.2; p=0.01), and late non-pelvic SPCs (HR1.2; p=0.03).CONCLUSIONS: RP with RT was associated with moderately increased risk of SPCs compared to RP alone. This observation should be thoroughly discussed at informed consent and considered during followup.",
author = "Felix Preisser and Elio Mazzone and Sophie Knipper and Sebastiano Nazzani and Marco Bandini and Shariat, {Shahrokh F} and Michele Marchioni and Zhe Tian and Fred Saad and Daniel Taussky and Alberto Briganti and Hartwig Huland and Markus Graefen and Derya Tilki and Karakiewicz, {Pierre I}",
year = "2020",
month = may,
doi = "10.5489/cuaj.6087",
language = "English",
volume = "14",
pages = "E173--E179",
journal = "CUAJ-CAN UROL ASSOC",
issn = "1911-6470",
publisher = "Canadian Medical Association",
number = "5",

}

RIS

TY - JOUR

T1 - Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy

AU - Preisser, Felix

AU - Mazzone, Elio

AU - Knipper, Sophie

AU - Nazzani, Sebastiano

AU - Bandini, Marco

AU - Shariat, Shahrokh F

AU - Marchioni, Michele

AU - Tian, Zhe

AU - Saad, Fred

AU - Taussky, Daniel

AU - Briganti, Alberto

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Tilki, Derya

AU - Karakiewicz, Pierre I

PY - 2020/5

Y1 - 2020/5

N2 - INTRODUCTION: We aimed to investigate the effect of radiotherapy (RT) in contemporary patients treated with radical prostatectomy (RP) compared to RP alone for non-metastatic prostate cancer (PCa) on the incidence of second primary cancers (SPCs).METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015), we identified patients with PCa as the only or first primary cancer, who underwent RP and RT or RP alone. Cumulative incidence plots and multivariable Cox regression models tested for SPC rate differences according to treatment type: RP and RT vs. RP alone. Subgroup analyses focused on pelvic, primary pelvic, and non-pelvic SPCs, as well as on late SPCs (>5 years after PCa diagnosis).RESULTS: Of 152 161 patients, 7.1% (n=10 870) received RP and RT. Overall, 6.6 vs. 5.0% developed SPCs after RP and RT vs. RP alone, respectively (p<0.001). Cumulative incidence rates at 10 years after PCa diagnosis for RP and RT vs. RP were 12.0 vs. 8.7% (p<0.001), 2.0 vs. 1.2% (p<0.001), 2.1 vs. 1.3% (p<0.001), and 9.9 vs. 7.4% (p<0.001) for overall SPCs, primary pelvic SPCs, overall pelvic SPCs, and non-pelvic SPCs, respectively. Multivariable Cox regression models revealed an increased risk after RP and RT vs. RP alone for overall (hazard ratio [HR] 1.2; p<0.001), primary pelvic (HR 1.5; p<0.01), pelvic (HR1.4; p<0.001), non-pelvic (HR1.1; p<0.01), late overall (HR 1.2; p=0.01), and late non-pelvic SPCs (HR1.2; p=0.03).CONCLUSIONS: RP with RT was associated with moderately increased risk of SPCs compared to RP alone. This observation should be thoroughly discussed at informed consent and considered during followup.

AB - INTRODUCTION: We aimed to investigate the effect of radiotherapy (RT) in contemporary patients treated with radical prostatectomy (RP) compared to RP alone for non-metastatic prostate cancer (PCa) on the incidence of second primary cancers (SPCs).METHODS: Within the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015), we identified patients with PCa as the only or first primary cancer, who underwent RP and RT or RP alone. Cumulative incidence plots and multivariable Cox regression models tested for SPC rate differences according to treatment type: RP and RT vs. RP alone. Subgroup analyses focused on pelvic, primary pelvic, and non-pelvic SPCs, as well as on late SPCs (>5 years after PCa diagnosis).RESULTS: Of 152 161 patients, 7.1% (n=10 870) received RP and RT. Overall, 6.6 vs. 5.0% developed SPCs after RP and RT vs. RP alone, respectively (p<0.001). Cumulative incidence rates at 10 years after PCa diagnosis for RP and RT vs. RP were 12.0 vs. 8.7% (p<0.001), 2.0 vs. 1.2% (p<0.001), 2.1 vs. 1.3% (p<0.001), and 9.9 vs. 7.4% (p<0.001) for overall SPCs, primary pelvic SPCs, overall pelvic SPCs, and non-pelvic SPCs, respectively. Multivariable Cox regression models revealed an increased risk after RP and RT vs. RP alone for overall (hazard ratio [HR] 1.2; p<0.001), primary pelvic (HR 1.5; p<0.01), pelvic (HR1.4; p<0.001), non-pelvic (HR1.1; p<0.01), late overall (HR 1.2; p=0.01), and late non-pelvic SPCs (HR1.2; p=0.03).CONCLUSIONS: RP with RT was associated with moderately increased risk of SPCs compared to RP alone. This observation should be thoroughly discussed at informed consent and considered during followup.

U2 - 10.5489/cuaj.6087

DO - 10.5489/cuaj.6087

M3 - SCORING: Journal article

C2 - 31793866

VL - 14

SP - E173-E179

JO - CUAJ-CAN UROL ASSOC

JF - CUAJ-CAN UROL ASSOC

SN - 1911-6470

IS - 5

ER -